{"title":"The Dilemma in the Management of Patients with Heart Failure with Reduced Ejection Fraction, Sinus Rhythm and Left Ventricular Spontaneous Echo Contrast: A Narrative Review.","authors":"Hedieh Alimi, Ali Tajik","doi":"10.2174/011573403X363285250519064030","DOIUrl":"https://doi.org/10.2174/011573403X363285250519064030","url":null,"abstract":"<p><p>Heart failure (HF) is a complex clinical syndrome that arises from structural or functional impairment of ventricular filling or ejection of blood, resulting in previous characteristic symptoms of fatigue, dyspnea, and fluid retention. Among the complications of heart failure is the development of spontaneous echo contrast (SEC), characterized by a smoke-resembling appearance on echocardiograms, which indicates blood stasis in heart chambers. Despite being identified as an echocardiographic marker in the left atrium that correlates with thrombus formation and causes thromboembolic events, the clinical importance of left ventricular spontaneous echo contrast (LV-SEC) and the appropriate management for patients with this condition remain uncertain due to insufficient data. Anticoagulant therapy is generally recommended for patients with established left ventricular thrombus (LVT). However, for patients with heart failure with reduced ejection fraction (HFrEF) and sinus rhythm (SR), as a result of a decrease in thromboembolic events over time, it is typically not recommended. The main challenge lies in assessing the thromboembolic risk and determining appropriate management in patients with HFrEF, sinus rhythm (SR), and left ventricular spontaneous echo contrast (LV-SEC), compared to those with left ventricular thrombus (LVT) and those with HFrEF and SR without LV-SEC. The aim of this paper is to review the guidelines and trials on clinical characteristics, outcomes, and management of patients with LV-SEC and compare the suggested management with the established management for LVT and HF patients with sinus rhythm without LV-SEC.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Haitian Li, Buxing Chen, GinChung Wang, Yunxiao Wang, Yang Yang
{"title":"Predicting Coronary Artery Lesion Severity Using Pulse Wave Harmonics: A SYNTAX Score-Based Study.","authors":"Haitian Li, Buxing Chen, GinChung Wang, Yunxiao Wang, Yang Yang","doi":"10.2174/011573403X400522250519073551","DOIUrl":"https://doi.org/10.2174/011573403X400522250519073551","url":null,"abstract":"<p><p>Introduction This study aimed to investigate the correlation between the differences in pulse wave harmonic indices between the left and right hands and the SYNTAX score and to explore the potential of pulse wave harmonics in predicting the degree of coronary artery lesions. Methods The arterial pressure wave signals from both hands of the patients scheduled for coronary angiography were recorded using photoplethysmography. According to the \"visceral resonance theory,\" taking integer multiples of the heartbeat from 0 to 11 as the resonance frequencies, the collected arterial pressure waves were decomposed into the 0th to 11th harmonics via the Fourier transform method. The harmonic characteristics were quantified by amplitude (Cn), phase (Pn), and energy (Dn) (n is the harmonic serial number), and the coefficient of variation of the indices was calculated and suffixed as CV. The difference between the measured values of the left- and right-hand parameters of the same patient was calculated (ΔCn,ΔPn,ΔDn,ΔCnCV,ΔPnCV), and the absolute value of the difference was obtained (|ΔCn|, |ΔPn|, |ΔDn|, |ΔCnCV|, |ΔPnCV|). Based on the coronary angiography imaging data, SYNTAX scores were computed for all participants, who were stratified by gender into male and female cohorts. For each group, logistic regression models were established with SYNTAX score≥22 as the dependent variable, and harmonic index differences as the independent variables. To determine the best prediction model, the Akaike Information Criterion (AIC) was used and model with the lowest score was selected. Finally, the discriminant ability of the prediction model was evaluated using the ROC curve analysis and the Bootstrap internal validation method. Results: A total of 348 patients were included, with 249 males and 99 females. In the male group, the discriminant model was based on |ΔC10|,ΔD6, |ΔD9|, |ΔD10|, |ΔP8|, |ΔP10|, ΔP1CV, and ΔC9CV, with the minimum AIC value of 105.47, the area under the ROC curve (AUC) of 0.89, and the average AUC of 0.85 in the Bootstrap internal validation. In the female group, the discriminant model was based on |ΔD2|, |ΔD3|, |ΔD5|, |ΔD6|, |ΔD9|, |ΔC2CV|, |ΔC4CV|, |ΔC5CV|, | ΔC6CV|, and |ΔC9CV|, with the minimum AIC value of 59.34. The AUC of the ROC curve of this prediction model was 0.92, and the average AUC in the Bootstrap internal validation was 0.84. Discussion In this study, the degree of coronary artery occlusion was evaluated through a noninvasive method combined with the SYNTAX score, providing a valuable noninvasive tool for clinical evaluation of CAD. This detection method is easy to operate, has high repeatability, and the equipment is small in size, making it suitable for various environments, it can be operated independently by the patients. Yet, the current study, being cross-sectional, only found an association rather than a causal relationship, calling for future prospective studies to clarify the causal link. Conclusion: The different ch","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Necip Fazıl Dedeoglu, Mustafa Begenc Tascanov, Kenan Toprak, Halil Fedai, Asuman Bicer, İbrahim Halil Altiparmak, Zulkif Tanriverdi, Recep Demirbag, Ismail Koyuncu
{"title":"The Association of Neuropeptide Y with the Presence and Frequency of Ventricular Premature Beats.","authors":"Necip Fazıl Dedeoglu, Mustafa Begenc Tascanov, Kenan Toprak, Halil Fedai, Asuman Bicer, İbrahim Halil Altiparmak, Zulkif Tanriverdi, Recep Demirbag, Ismail Koyuncu","doi":"10.2174/011573403X361970250507035931","DOIUrl":"https://doi.org/10.2174/011573403X361970250507035931","url":null,"abstract":"<p><strong>Background: </strong>The estimated prevalence of ventricular extra systole (VES) in the general population is about 1-4% on ECG, but 24-hour Holter monitoring has shown a prevalence of 40-75%. While it may be asymptomatic in many patients, frequent VES persisting for a long time can negatively affect left ventricular (LV) systolic function in patients without structural heart disease. The etiology of VES is not completely known. In this study, we investigated the role of neuropeptide Y (NPY) in the occurrence of VES.</p><p><strong>Material and methods: </strong>In this study, we included 150 patients with VES and 86 cases without VES as the control group. 24-hour Holter monitoring was performed on all subjects. Patients with VES were divided into two subgroups according to the frequency of VES as those >15,000 (Group 1, n= 48) and <15,000 (Group 2, n= 102). Venous blood was collected from all cases for biochemistry parameters and NPY level measurement.</p><p><strong>Results: </strong>There were statistically significant differences between the two groups in terms of gender, smoking, LVEF, NPY, total cholesterol, LVEDD, SDNN, SDNNINDEX, RMSD, PNN50, LF, HF, VLF, and LF/HF (p<0.05, for all). Correlation analysis showed a significant positive correlation between serum NPY level and number of VES (r=0.577, p=0.001), LF (r=0140, p=0.032), LVEDD (r=0.162, p=0.013), and LVESD (r=0.290, p=0.001). Conversely, a negative correlation was observed between NPY and RMSSD (r=-0.162, p=0.012), SDNNINDEX (r=-0.136, p=0.037). Multivariate logistic regression analysis showed that NPY (odds ratio [OR]: 1.204; 95% confidence interval [CI]: 1.103-1.315; p=0.001) was an independent predictor of VES development. ROC curve analysis showed that NPY ≥ 47.9 ng/L predicted the occurrence of VES with a sensitivity of 82.0% and specificity of 81.4%. In addition, NPY ≥ 79.8 predicted the frequency of VES with a sensitivity of 85.5% and specificity of 87.3 %.</p><p><strong>Conclusion: </strong>Our study showed that serum NPY levels may play an important role in the development of VES. Also, it was found that the frequency of VES increased as the NPY level increased.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharmacological Foundation and Novel Insights of Resveratrol in Cardiovascular System: A Review.","authors":"Ruchi Tiwari, Gaurav Tiwari, Anju Singh, Namdev Dhas","doi":"10.2174/011573403X343252250502045328","DOIUrl":"https://doi.org/10.2174/011573403X343252250502045328","url":null,"abstract":"<p><p>Research into drugs that can enhance cardiovascular health has been sparked by the rising prevalence of cardiovascular illnesses (CVDs). In addition to its anti-inflammatory and antioxidant qualities, Resveratrol (RES) is well known for its capacity to increase endothelial NO synthase (eNOS) activity. This page summarises RES's wide effects on energy metabolism, resilience to stress, exercise mimicking, circadian rhythm, lifespan control, and microbiome composition. This article addresses the poor and contradictory results shown in preclinical and clinical trials provides an update on the cardiovascular preventive properties of RES. The activation of AMP-activated protein kinase (AMPK), silent information regulator 1 (SIRT1), and natural antioxidant enzymes is associated with some of the positive effects of RES on the cardiovascular system. A microarray data summary indicates a strong correlation between the heart's reaction to calorie restriction and the transcriptional responses to RES. RES has been demonstrated to reduce contractile dysfunction, cardiac remodelling, and hypertrophy in several animal models of heart failure. Its preventive properties are believed to be due to several molecular pathways, including the suppression of prohypertrophic signalling molecules, enhancement of cardiac Ca2+ handling, control of autophagy, and decreases in inflammation. RES thus has the potential to be used in several novel therapeutic approaches for treating diseases such as atherosclerosis, ischemia/reperfusion damage, metabolic syndrome, heart failure, and inflammatory changes associated with ageing.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Antiplatelet-Proton Pump Inhibitor Interactions and Arterial Thrombotic Events: A Pharmacovigilance Assessment Using Disproportionality and Interaction Analysis.","authors":"Kannan Sridharan","doi":"10.2174/011573403X374906250417043907","DOIUrl":"https://doi.org/10.2174/011573403X374906250417043907","url":null,"abstract":"<p><strong>Aims: </strong>The aim of this study is to evaluate the safety profiles of antiplatelet-proton pump inhibitors (PPIs) combinations and assess the clinical implications of their concurrent use in real-world settings through pharmacovigilance data analysis.</p><p><strong>Background: </strong>The concomitant use of PPIs with antiplatelet therapy remains controversial due to potential drug interactions affecting clinical outcomes. While PPIs are recommended for gastroprotection in patients receiving antiplatelet therapy, concerns persist regarding their impact on antiplatelet efficacy, particularly with dual antiplatelet therapy (DAPT).</p><p><strong>Objectives: </strong>The objective of this study is to analyze and compare the thrombo-embolic risk profiles of various antiplatelet-PPI combinations using the FDA Adverse Event Reporting System database.</p><p><strong>Methods: </strong>We conducted a comprehensive analysis of the FDA Adverse Event Reporting System (FAERS) database to evaluate the thrombo-embolic risk associated with antiplatelet-PPI combinations. The reporting odds ratio (ROR) and information component were calculated to detect safety signals. The interaction signal score (INTSS) was used to assess the protective or harmful effects of adding acetylsalicylic acid to clopidogrel-PPI combinations.</p><p><strong>Results: </strong>Analysis revealed significant safety signals for thrombo-embolic events with clopidogrel-rabeprazole (ROR: 62.67, 95% CI: 38.38-102.32) and clopidogrel-omeprazole (ROR: 6.87, 95% CI: 4.89-9.66) combinations. DAPT-PPI combinations showed comparable safety profiles to monotherapy-PPI combinations. The INTSS analysis suggested a potential protective effect of acetylsalicylic acid when added to clopidogrel-PPI combinations. Genderspecific analysis revealed female predominance in monotherapy complications and male predominance in combination therapy events. Clinical outcomes, including mortality and hospitalization rates, were comparable between groups.</p><p><strong>Conclusion: </strong>This pharmacovigilance analysis suggests that while DAPT-PPI combinations demonstrate acceptable safety profiles, careful consideration should be given to PPI selection, particularly given the unexpected safety signals with rabeprazole and confirmed risks with omeprazole. The addition of acetylsalicylic acid to clopidogrel-PPI combinations may offer protective effects against thrombo-embolic events. These findings support individualized riskbenefit assessment in selecting antiplatelet-PPI combinations while ensuring adequate gastroprotection for high-risk patients.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evolving Strategies in the Detection and Management of Left Ventricular Thrombus: A Clinical Summary.","authors":"Mahmoud Abdelnabi, Ramzi Ibrahim, Hoang Nhat Pham, Yehia Saleh, Abdallah Almaghraby","doi":"10.2174/011573403X364065250429095440","DOIUrl":"https://doi.org/10.2174/011573403X364065250429095440","url":null,"abstract":"<p><p>Recent advancements have emerged in understanding the epidemiology and optimal therapeutic options for left ventricular thrombi (LVT). With early percutaneous interventions in acute myocardial infarction, the prevalence of LVT has decreased. However, the best strategies for prevention, risk stratification, and management remain unclear, especially among nonischemic cardiomyopathy disorders. This review outlines these advancements and provides an overview of the diagnostic and therapeutic implications of LVT in ischemic and non-ischemic cardiomyopathies. Significant gaps in the current evidence persist, particularly regarding the optimal timing for LVT screening and the need for prophylactic anticoagulation, highlighting opportunities for prospective cohort studies. Furthermore, a better understanding of the unique risk factors that contribute to increased LVT risk would lead to more comprehensive algorithms that may quantify the risk of LVT development, aiding in developing preventive strategies targeted at reducing rates of LVT. Until more definitive evidence is available, clinicians should custom LVT screening, preventive measures, and management strategies based on individual patient risk factors.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Emerging Roles of Resolvins: Potential Diagnostic Biomarkers for Cardiovascular Diseases.","authors":"Reyhan Bolat, Burak Yazgan","doi":"10.2174/011573403X370785250417015007","DOIUrl":"https://doi.org/10.2174/011573403X370785250417015007","url":null,"abstract":"<p><p>Cardiovascular diseases (CVDs) are the leading cause of death worldwide and include a range of conditions affecting the heart and vascular system. There is a growing priority on identifying and validating biomarkers for CVDs to increase early diagnosis and survival rates. Within this framework of research, there has been a notable increase in interest in resolvins, a class of specialized pro-resolving mediators. Resolvins are well-known for their capacity to promote tissue healing and reduce inflammation. They are categorized into three series: Dseries (RvD1 to RvD6), T-series (RvT1 to RvT4), and E-series (RvE1 to RvE4). These molecules are produced through biochemical pathways involving enzymes such as lipoxygenase (LOX), cyclooxygenase (COX), and cytochrome P450 (CYP). These enzymes utilize precursor molecules like docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and docosapentaenoic acid (DPA). This review addresses a critical gap in the literature by evaluating the potential of resolvins as biomarkers for the diagnosis and prognosis of cardiovascular diseases. By synthesizing existing knowledge on their production pathways and receptors, it highlights the implications of altered resolvins levels in disease mechanisms and offers new perspectives on their clinical relevance.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Syed Shadab Ahmad, Javed Akhtar Ansari, Tarique Mahmood Ansari, Syed Mehdi Hasan Zaidi
{"title":"Mitochondrial Dysfunction in Cardiac Diseases: Insights into Pathophysiology and Clinical Outcomes.","authors":"Syed Shadab Ahmad, Javed Akhtar Ansari, Tarique Mahmood Ansari, Syed Mehdi Hasan Zaidi","doi":"10.2174/011573403X379197250417061904","DOIUrl":"https://doi.org/10.2174/011573403X379197250417061904","url":null,"abstract":"<p><p>Mitochondrial dysfunction plays a crucial role in the pathogenesis of various cardiac diseases, including heart failure, ischemic cardiomyopathy, and drug-induced cardiotoxicity. Mitochondria are essential for cellular energy production, calcium homeostasis, redox balance, and apoptotic regulation, making their proper function vital for cardiac health. Dysfunctional mitochondria contribute to excessive reactive oxygen species (ROS) production, impaired ATP synthesis, and disruption of mitochondrial dynamics, leading to cardiomyocyte damage and cell death. Emerging research highlights mitochondrial dynamics, including fission, fusion, mitophagy, and biogenesis, as critical determinants of cardiac homeostasis. Perturbations in these processes exacerbate myocardial injury and heart failure progression. Additionally, chemotherapy-induced cardiotoxicity, primarily from anthracyclines, is closely linked to mitochondrial damage, underscoring the need for targeted therapeutic strategies. Pharmacological interventions, such as antioxidants, mitochondrial-targeted drugs, and cardioprotective agents, have shown promise in mitigating mitochondrial dysfunction-related cardiac toxicity. Furthermore, lifestyle modifications, including exercise and dietary interventions, are being explored to enhance mitochondrial resilience in cardiac tissues. Advanced imaging techniques and biomarker-based diagnostics are improving the early detection of mitochondrial dysfunction in cardiac diseases. Emerging therapeutic strategies, such as mitochondrial transplantation, gene therapy, and precision medicine approaches, hold potential for targeted intervention. Despite these advances, challenges remain in translating mitochondrial-targeted therapies into clinical practice due to complexities in mitochondrial regulation and inter-organ communication. Future research should focus on optimizing mitochondrial-targeted interventions, improving diagnostic precision, and exploring novel molecular pathways to mitigate cardiac mitochondrial dysfunction. A comprehensive understanding of mitochondrial pathophysiology in cardiac diseases will pave the way for innovative treatment strategies aimed at preserving cardiac function and reducing the burden of heart failure.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Navigating Cardiotoxicity in Cancer Treatment: Insights into Fluoropyrimidine-Induced Cardiac Events.","authors":"Ashika Bhattarai, Manodeep Chakraborty, Md Hasnat Jahan Ali, Chetiz Sharma, Akanchya Rai, Rudra Acharya, Yuan Rai, Ananya Bhattacharjee, Nihar Ranjan Bhuyan","doi":"10.2174/011573403X335593250413154832","DOIUrl":"https://doi.org/10.2174/011573403X335593250413154832","url":null,"abstract":"<p><strong>Background: </strong>Fluoropyrimidine (FP) is a key cancer treatment but often causes side effects, notably cardiotoxicity. This cardiotoxicity can present as angina, arrhythmia, dyspnea, and palpitations, requiring urgent cardiologist attention. The etiology, management, and frequency of FP-induced cardiotoxicity are still unknown despite long-term use.</p><p><strong>Objective: </strong>The article aims to provide an overview of the pathogenic occurrence, cardiac event risk factor, possible underlying mechanism of FP-cardiotoxicity, diagnostics, and therapeutic approach for the corrective management of this clinical condition.</p><p><strong>Methods: </strong>review was performed by searching extensively for various existing literature search PubMed, Web of science and Scopus using suitable keywords to find articles that support our review study.</p><p><strong>Result: </strong>FP induced cardiotoxicity results in morbidness and fatality in patient undergoing the treatment. Thus, an effective management system must be standardized to effectively treat and prevent this clinical condition.</p><p><strong>Conclusion: </strong>the cardiotoxic event following 5-FU has been lesser-known clinical entity with limited study on its pathophysiology and management. In the diagnosis procedure, each patient undergoing FP treatment ought to have early symptom identity, risk categorization, and therapy individualized based on benefit-risk ratio.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Risk of Cardiovascular Diseases Associated with PCOS in India: A Review.","authors":"Amandeep Kaur, Ranjeet Kumar, Hardik Kumar, Sonakshi Garg, Abhishek Vijukumar, Dharmendra Kumar","doi":"10.2174/011573403X349035250408050637","DOIUrl":"https://doi.org/10.2174/011573403X349035250408050637","url":null,"abstract":"<p><p>In the modern world, Polycystic Ovary Syndrome (PCOS) is thought to be the most prevalent endocrine condition affecting women. Compared to their normal counterparts, PCOS patients have higher rates of morbidity and death because they are more susceptible to these anomalies from an early age. Cardiovascular disease (CVD) and PCOS are prevalent in women. PCOS often results from a combination of hereditary and environmental causes. Insulin resistance (IR) is considered the primary cause of several metabolic risk factors, such as Type 2 Diabetes Mellitus (T2DM), Metabolic Syndrome (MetS), dyslipidemia, obesity, and hypertension (HTN). Additionally, patients with PCOS may also have elevated levels of non-traditional factors, including C-reactive protein (CRP), carotid intima-media thickness (IMT), coronary artery calcification (CAC), as well as endothelial dysfunction, which raises the likelihood of complications from CVD. This review utilizes statistics and data mostly sourced from research in India, offering insight into the nation's distinct PCOS prevalence and related cardiovascular risks. To lessen the impact of PCOS in the modern world, prompt identification and effective management of these warning signs with food, lifestyle changes, and/or medication are crucial. The research that examined the potential impact of PCOS on the most prevalent CVD-hypertension, insulin resistance, obesity, malignancy, diabetes mellitus, and dyslipidemia-is reviewed in this study. Measuring subclinical atherosclerosis, such as coronary artery calcium or carotid plaque, might help inform shared decision-making over the start of statin therapy when CVD risk is unknown.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}